BioSpace News Archive

Drug Development

DiaMedica Ischemic Stroke Program Hits Another Bump in the Road

DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.

July 7, 2022
·
3 min read
·
Hannah Chudleigh
Drug Development

Money on the Move: Precigen, Syros, Zhiyi and Agile Raise Capital

As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.

July 7, 2022
·
3 min read
·
Hannah Chudleigh
Policy

AbbVie’s Tax Structure in Crosshairs of Senate Finance Committee Report

A Senate Finance Committee report shows the majority of AbbVie’s income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.

July 7, 2022
·
3 min read
·
Alex Keown
Japanese Study Suggests Parasitic Worms could Deliver Anti-Cancer Therapies

Researchers from Osaka University have released details on how they discovered a unique, albeit strange, potential treatment method for cancer - parasitic worms.

July 7, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
Researchers Identify Key to Developing Effective Staph Vaccines in Humans

Facing the looming threat of AMR, researchers finally have a new clue as to why attempts to develop an effective S. aureus vaccine have failed. BioSpace spoke with the team leaders.

July 7, 2022
·
4 min read
·
Gail Dutton
Biotech Bay

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus ConferencePresident Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets

Tempest Therapeutics, Inc. today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech Focus Conference on Tuesday, July 12, 2022 at 4:10 p.m. ET.

July 7, 2022
·
1 min read
Drug Development

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011,

July 7, 2022
·
5 min read
Business

Encompass Health announces date of 2022 second quarter earnings call

Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2022 , after the market closes on August 1, 2022.

July 7, 2022
·
1 min read
Policy

CovClear COVID-19 Antigen Self-Test Extends Expiration Date in Canada

Empowered Diagnostics, Inc. announced that the Company has received approval from Health Canada to extend the shelf life of CovClear COVID-19 Rapid Antigen Test from 12 months to 24 months.

July 7, 2022
·
1 min read
BioMidwest

INVO Bioscience Announces “Get to Know INVOcell” - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment

INVO Bioscience, Inc. announced that Dr. Sue Ellen Carpenter of Bloom Fertility, an INVO Center in Atlanta, will be hosting “Get to Know INVOcell” - a Facebook Live Event on July 7, 2022 at 7 PM ET.

July 7, 2022
·
4 min read